secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annexon, Inc. (ANNX)
CIK:        0001528115
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0001193125-24-133086
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annexon presents positive Phase 2 data for ANX007 in GA; plans Phase 3 trials in 2024
--------------------------------------------------------------------------------

- ANX007 showed 73% relative risk reduction in BCVA 15-letter loss at 12 months in Phase 2 ARCHER trial.
- Statistically significant slowing of low luminance visual acuity loss and reduction in photoreceptor loss observed.
- No choroidal neovascularization increase and no cases of vasculitis; generally well-tolerated safety profile.
- Global pivotal Phase 3 ARCHER II (vs sham) expected mid-2024; Phase 3 ARROW (vs SYFOVRE) expected H2 2024.
- Preclinical data show C1q blockade protects photoreceptor synapses and preserves retinal function in GA models.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1528115/000119312524133086/0001193125-24-133086-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1528115/000119312524133086/d825274d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-133086

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer